MD Conference Express - ELCC 2015 - (Page 2)

FEATURED ARTICLES The Road to Patient-Based Therapy for NSCLC Written by Mary Mosley The emergence of molecular targets identified by genotyping tumors in patients with non-small cell lung cancer (NSCLC) has led to the development of new drugs to manage NSCLC. Next-generation sequencing (NGS) is now being used to identify subsets of patients who are sensitive or resistant to specific drugs and to identify new therapeutic targets that can be tested in clinical trials with novel compounds. This transition from pathologic-guided treatment of NSCLC to target-based treatment will be followed by patient-based therapy specific to genetic alterations identified by NGS. A new paradigm for clinical trials of targeted therapies that includes testing of new predictive biomarkers was reviewed in this session, along with clinical research in France and Germany that has employed target-based treatment. BIOGUIDED TREATMENT MAY IMPROVE OUTCOMES Peer-Reviewed Highlights From the European Society for Medical Oncology 2015 European Lung Cancer Conference April 15-18, 2015 Geneva, Switzerland A network of genetic centers was established in France by its National Cancer Institute for the routine analysis in daily practice of targetable oncogenes and biomarkers using NGS and to conduct clinical trials, stated Fabrice Barlesi, MD, Aix Marseille University, Marseille, France. The Biomarkers France study in patients with advanced NSCLC was conducted to determine whether it was possible to match the drug to the oncogenic driver for so-called bioguided treatment that is patient specific and improves outcomes. This study prospectively collected into a centralized database nearly 19 400 molecular analyses and the epidemiologic, clinical, and therapeutic data from the 17 664 corresponding patients. The preliminary findings from 10 000 biomarker analyses were previously reported [Barlesi F et al. ASCO 2013 (abstr 8000)]. The final results have been submitted for publication and could not be presented. An indication of the final results for the Biomarkers France study may come from a local study conducted at the same time by Prof Barlesi and colleagues in their hospital and a study conducted in the United States. However, the latter 2 studies were limited to adenocarcinoma (ADC), while the Biomarkers France study is not. The local study included 262 patients with stage IV ADC of the lung diagnosed between 2012 and 2013; the genetic profile is shown in Figure 1. An oncogenic Figure 1. Genetic Profile in Local Study of 262 Patients HER2 1% EGFR 11% Unknown/other 56% KRAS 27% BRAF 2% PI3K 1% ALK 2% Reproduced with permission from F Barlesi, MD. 2 May 2015 www.mdce.sagepub.com http://mdc.sagepub.com/

Table of Contents for the Digital Edition of MD Conference Express - ELCC 2015

Contents

MD Conference Express - ELCC 2015